NCT02868359

Brief Summary

The purpose of this study is to evaluate the effect of pregabalin on patient reported outcomes compared with conventional analgesic care in chronic cervical pain patients with accompanying upper limb radiating pain (neuropathic component) treated in primary care settings under routine clinical practice.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
369

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Oct 2016

Geographic Reach
1 country

33 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

August 9, 2016

Completed
7 days until next milestone

First Posted

Study publicly available on registry

August 16, 2016

Completed
2 months until next milestone

Study Start

First participant enrolled

October 1, 2016

Completed
1.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 24, 2017

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

October 24, 2017

Completed
Last Updated

January 20, 2021

Status Verified

January 1, 2019

Enrollment Period

1.1 years

First QC Date

August 9, 2016

Last Update Submit

January 15, 2021

Conditions

Outcome Measures

Primary Outcomes (1)

  • Change From Baseline at 8 weeks in Pain Related Sleep Interference Scale (PRSIS - Past Week Recall)

    The Pain Related Sleep Interference Scale (past week recall) consists of an 11-point numeric rating scale (NRS) ranging from 0 (pain did not interfere with sleep) to 10 (pain completely interfered with sleep). Subjects are to describe how their pain has interfered with their sleep during the past week by choosing the appropriate number between 0 and 10.

    Baseline, Visit 2 (week 4), Final visit (week 8 or discontinuation)

Secondary Outcomes (7)

  • Change From Baseline in Neck Disability Index (NDI)

    Baseline, Visit 2 (week 4), Final visit (week 8 or discontinuation)

  • Change From Baseline in Pain Numeric Rating Scale (Pain NRS - past week recall)

    Baseline, Visit 2 (week 4), Final visit (week 8 or discontinuation)

  • Change From Baseline in Euro Qol- 5 Dimensions -5 Level (EQ-5D-5L)-QOL-Score-

    Baseline, Visit 2 (week 4), Final visit (week 8 or discontinuation)

  • Change From Baseline in Euro Qol- 5 Dimensions -5 Level (EQ-5D-5L)-Visual Analogue Scale -

    Baseline, Visit 2 (week 4), Final visit (week 8 or discontinuation)

  • Clinical Global Impression of Change (CGIC)

    Final visit (week 8 or discontinuation)

  • +2 more secondary outcomes

Study Arms (2)

Pregabalin / Other analgesics

Patients will be treated for 8 weeks with pregabalin in primary care: no intervention

Other: No Intervention

Other analgesics

Patients will be treated for 8 weeks with other analgesics in usual care: no intervention

Other: No Intervention

Interventions

The study is observational.

Other analgesicsPregabalin / Other analgesics

Eligibility Criteria

Age20 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Chronic cervical pain patients with accompanying upper limb radiating pain (neuropathic component) treated with pregabalin or other analgesics

You may qualify if:

  • Subject who received the enough study information and signed informed consent form.
  • Subject who had chronic pain with accompanying radiating pain to the superior limb beyond the elbow.
  • Subject is male or female patient ≧20 years old. Subject who reported neck pain with accompanying radiating pain to superior limb (12 weeks or greater in duration at Visit 0).
  • Subject who is refractory to previous analgesics for 12 weeks and more. Subject who is able and willing to complete all study related assessment tools and complied with scheduled clinic visits and clinical study procedures.
  • Subject whose pain NRS ≧5 and PRSIS ≧1 at baseline (based on recall over the past week).

You may not qualify if:

  • Subject who, in the opinion of the investigator, was not likely to complete the trial for whatever reason.
  • Subject who was treated with Pregabalin within the past 12 weeks (on baseline). Subject who has been regularly treated cervical pain with nerve blocks (such as stellate ganglion block, epidural block, radicular block and trigger point injection etc.).

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (33)

Satoh Orthopaedic Clinic

Ichikawa, Chiba, 272-0021, Japan

Location

Shiraishi Orthopaedic Clinic

Ichikawa, Chiba, 272-0138, Japan

Location

Clinic for Sports Medicine and Nutrition

Fukuoka, Fukuoka, 810-0022, Japan

Location

Seiwa Orthopedics Surgery Internal Medicine

Fukuoka, Fukuoka, 812-0041, Japan

Location

Kiheikai Yoh Orthopedic Clinic

Fukuoka, Fukuoka, 812-0046, Japan

Location

Chihaya Hospital

Fukuoka, Fukuoka, 813-8501, Japan

Location

Fukuoka Mirai Hospital

Higashi-ku,Fukuoka, Fukuoka, 813-0017, Japan

Location

Shin Komonji Hospital

Kitakyusyu-shi, Fukuoka, 800-0057, Japan

Location

Fukushima Daiichi Hospital

Fukushima, Fukushima, 960-8251, Japan

Location

Takasaki Pain Clinic

Takasaki-shi, Gunma, 370-0035, Japan

Location

Miyanomori Memorial Hospital

Sapporo, Hokkaido, 064-8570, Japan

Location

Oomuro Orthopedic Clinic

Himeji-shi, Hyōgo, 670-0976, Japan

Location

Oonishi Medical Clinic

Kako-gun, Hyōgo, 675-1115, Japan

Location

Watanabe Orthopaedic Clinic

Kobe, Hyōgo, 657-0824, Japan

Location

Fujisawa Shonandai Hospital

Fujisawa-shi, Kanagawa, 252-0802, Japan

Location

Ando Orthopaedics Hospital

Kawasakishi, Kanagawa, 213-0001, Japan

Location

General Sagami Kosei Hospital

Sagamiharashi, Kanagawa, 252-5225, Japan

Location

Arai Orthopaedic Clinic

Saitama, Kanagawa, 356-0004, Japan

Location

Saitoh Orthopedic Sports Clinic

Yamato-shi, Kanagawa, 242-0024, Japan

Location

Ageo Medical Clinic

Ageo, Saitama, 362-0021, Japan

Location

Nakaicho Clinic

Adachi City, Tokyo, 120-0033, Japan

Location

Kyobashi Orthopaedic Clinic

Chūō, Tokyo, 104-0031, Japan

Location

Morishima Clinic

Edogawa City, Tokyo, 133-0057, Japan

Location

Shinkoiwa Ekimae Sogo Clinic

Katsushika-ku, Tokyo, 124-0024, Japan

Location

Meguro Seikeigeka Naika

Meguro City, Tokyo, 152-0002, Japan

Location

Meguro Yuai Clinic

Meguro City, Tokyo, 153-0065, Japan

Location

Takemoto Orthopaedic Clinic

Ohta, Tokyo, 145-0066, Japan

Location

Ohimachi Orthopaedic Clinic

Shinagawa, Tokyo, 140-0014, Japan

Location

Shinjuku Research Park Clinic

Shinnzyuku, Tokyo, 169-0073, Japan

Location

Kouenji Orthopedic Clinic

Suginami, Tokyo, 166-0003, Japan

Location

Daido Hospital

Toshima City, Tokyo, 171-0033, Japan

Location

Saga-ken Medical Center Koseikan

Saga, 840-8571, Japan

Location

Tokyo Rheumatism Pain Clinic

Tokyo, 104-0031, Japan

Location

Related Publications (1)

  • Taguchi T, Nozawa K, Parsons B, Yoshiyama T, Ebata N, Igarashi A, Fujii K. Effectiveness of pregabalin for treatment of chronic cervical radiculopathy with upper limb radiating pain: an 8-week, multicenter prospective observational study in Japanese primary care settings. J Pain Res. 2019 May 3;12:1411-1424. doi: 10.2147/JPR.S191906. eCollection 2019.

Related Links

MeSH Terms

Conditions

Neck PainNeuralgiaPain

Condition Hierarchy (Ancestors)

Neurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and SymptomsPeripheral Nervous System DiseasesNeuromuscular DiseasesNervous System Diseases

Study Officials

  • Pfizer CT.gov Call Center

    Pfizer

    STUDY DIRECTOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 9, 2016

First Posted

August 16, 2016

Study Start

October 1, 2016

Primary Completion

October 24, 2017

Study Completion

October 24, 2017

Last Updated

January 20, 2021

Record last verified: 2019-01

Data Sharing

IPD Sharing
Will not share

Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical\_trials/trial\_data\_and\_results/data\_requests.

Locations